Physiologas Selected for Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project (AMDAP) for Home Hemodialysis Development

Physiologas Technologies Inc. (Headquarters: Sagamihara, Kanagawa; Representative Director: Kazuyoshi Miyawaki; hereinafter "the Company") is pleased to announce that it has been selected as a grant recipient for the Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project (AMDAP), which supports the development of advanced medical devices by startups and SMEs. The grant provides up to 600 million yen over a maximum of six years.

■ Business Plan Name: Development of a Home Hemodialysis Device That Does Not Require Tap Water Connection

■ Business Plan Overview:

・Hemodialysis treatment at clinics imposes significant time and physical burdens on patients. Current home hemodialysis devices are large because they require dedicated plumbing for water supply and drainage, and are difficult for patients to operate as they are designed for medical professionals.

・By utilizing technology that recirculates dialysate within the system, we are developing a compact home hemodialysis device that eliminates the need for plumbing and is easy for patients to operate at home.

■ Maximum Grant Amount: Up to 600 million yen over a maximum of 6 years.

For details on the Tokyo Metropolitan Government's selection announcement, please refer to the following links:

https://www.metro.tokyo.lg.jp/information/press/2026/03/2026032625

https://amdap.metro.tokyo.lg.jp/

With this selection, we will accelerate the social implementation of home hemodialysis to improve the quality of life for end-stage renal disease patients and their families.

About the Advanced Medical Device Acceleration Project (AMDAP)

The medical device industry is expected to see sustainable global growth. However, while domestic manufacturers have strengths in diagnostic equipment, Japan relies heavily on imports from Western manufacturers for therapeutic devices, which represent a larger market share and higher growth potential. This means Japan's renowned high-quality manufacturing is not being fully utilized. Tokyo, however, possesses high potential for medical device development due to the concentration of experts in clinical evaluation, regulations, insurance systems, business, and finance.

This project provides intensive support for business plans from startups and SMEs with high development potential, offering guidance and advice from experts in various fields. The most promising plans receive R&D subsidies, including clinical trial costs (up to 600 million yen over 6 years).

About Home Hemodialysis

In Japan, 340,000 end-stage renal disease patients undergo standard hemodialysis at clinics for four hours, three times a week, which is a treatment method with significant time and physical constraints. Conversely, home hemodialysis is known to offer higher patient quality of life and better clinical outcomes due to the ability to perform frequent treatments without the need for clinic visits.

However, because there are no dialysis devices specifically developed for home use in Japan, patients must install large, complex clinic-grade machines that require specialized plumbing and water quality management. Consequently, home hemodialysis is rarely practiced, with only about 800 patients currently utilizing it.

About Our Project

Based on research by Kenichi Kokubo (Associate Professor at Kitasato University School of Allied Health Sciences and CTO of our company), we are developing a compact, safe, home-use hemodialysis device that recirculates dialysate by adsorbing and removing uremic toxins.

The introduction of our device will enable frequent dialysis without clinic visits, which is expected to improve clinical outcomes. Furthermore, by enhancing the quality of life for patients and their families, we anticipate significant social impact, including the reintegration of patients into society and the workforce, leading to high economic utility.

About Physiologas Technologies Inc.

Founded in 2020 as a startup from Kitasato University, Physiologas Technologies Inc. operates under the purpose of "Innovating medicine through technology to deliver a happier life to patients and their families."